<DOC>
	<DOCNO>NCT02074280</DOCNO>
	<brief_summary>Cirrhotic patient predispose intestinal dysmotility , bacterial overgrowth , increase intestinal permeability lead increase bacterial translocation increase endotoxemia . Rifaximin antibiotic virtually non-absorbed oral administration exhibit broad spectrum antimicrobial activity aerobic anaerobic gram-positive gram-negative microorganism within gastrointestinal tract . It suggest oral prophylactic antibiotic bowel decontamination might improve long-term outcome patient cirrhosis . The aim study explore suitable dose rifaximin alleviate endotoxemia prevent complication advance cirrhosis .</brief_summary>
	<brief_title>Rifaximin Predicts Complications Decompensated Cirrhosis</brief_title>
	<detailed_description>Cirrhotic patient predispose intestinal dysmotility , bacterial overgrowth , increase intestinal permeability lead increase bacterial translocation increase endotoxemia . Cirrhotics bacterial translocation endotoxemia manifest hemodynamic derangement low systemic vascular resistance , high cardiac output , low mean arterial pressure . Moreover , endotoxin may increase portal pressure increase vascular resistance may promote cytokine-stimulated intrahepatic release endothelin cyclo-oxygenase product . Indeed , bacterial infection common cirrhotic patient approximately 30 % mortality one month 30 % mortality 12 month document systematic review comprise almost 12 000 patient . It follow alter gut flora decrease endotoxin level may lead improved prognosis cirrhosis . Rifaximin antibiotic virtually non-absorbed oral administration exhibit broad spectrum antimicrobial activity aerobic anaerobic gram-positive gram-negative microorganism within gastrointestinal tract . It suggest oral prophylactic antibiotic bowel decontamination might improve long-term outcome patient cirrhosis , reduce risk infection also reduce hepatic vein pressure gradient ( HVPG ) . The aim study explore suitable dose rifaximin alleviate endotoxemia prevent complication advance cirrhosis .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Rifaximin</mesh_term>
	<mesh_term>Rifamycins</mesh_term>
	<criteria>Decompensated cirrhosis ChildPugh B C stage severe complication cirrhosis past one month . renal dysfunction . administration antibiotic past two week . malignant tumor . HIV infection . severe heart lung disease sensitivity rifaximin Pregnancy lactation woman Patients take part clinical trial past three month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>rifaximin</keyword>
	<keyword>endotoxemia</keyword>
	<keyword>cirrhosis</keyword>
	<keyword>advanced cirrhosis</keyword>
</DOC>